Summary
| INTRODUCTION
Chronic hepatitis B virus (HBV) infection remains a major global health problem with most African countries and many Asian countries still classified as highly endemic areas.
1 Treatment options for chronic HBV infection include either peginterferon alfa administered for a finite duration or nucleos(t)ide analogues (NUCs) administered for several years and often for life. A disadvantage of long-term NUC administration is the selection for HBV variants that confer resistance to these drugs. These variants are termed primary drug resistance (DR) variants and are more commonly associated with NUCs that have a low genetic barrier to drug resistance such as lamivudine, adefovir and telbivudine than NUCs with a high barrier to drug resistance such as entecavir and tenofovir. HBV-DR variants are selected during NUC treatment because they can overcome suppression by the NUC used but they generally have less replication fitness. 2, 3 However, additional mutations that restore replication fitness may be selected during long-term treatment with NUCs. 4 These mutations are called secondary or compensatory HBV-DR variants.
Selection of primary HBV-DR variants can lead to virological and biochemical breakthrough, hepatitis flares, hepatic decompensation and even death.
While most HBV-DR variants are selected during NUC therapy, they can also be present in patients with chronic HBV infection who have never been treated with NUCs because HBV replicates through an error prone reverse transcription of pregenomic RNA to HBV DNA. This is further compounded by very high rates of HBV replication of up to 10 12 virions per day in some patients. It has also been suggested that HBV-DR variants may be transmitted from patients receiving
NUCs to HBV-susceptible persons. 5 This is of most concern in countries where NUCs with low barrier to resistance are frequently used as first-line therapy. A meta-analysis of 106 studies examining the prevalence of HBV-DR variants in 12 212 persons with chronic HBV infection who had never received NUCs found an overall prevalence of 5.73% (95% confidence interval [CI]: 4.85%-6.61%); however, there were wide geographical variations ranging from 20% in Africa to 0% in Brazil. 6 An important reason for the wide range in results is differences in sensitivities of assays used to detect DR variants. Sensitivities of assays used in these studies range from Sanger or population sequencing which can only detect variants present in ≥20% of the virus pool, line probe (reverse hybridization assay) or mass spectrometry which can detect variants present in roughly 5% of the virus pool, to next generation sequencing (NGS) which can detect variants present in <1% of the virus pool. 
| METHODS

| Study population
The HBRN is a cooperative network of investigators funded by the Details of the HBRN Cohort Study protocol and characteristics of the adult participants had been previously described. 8 Institutional review board or ethics committee approval was obtained from all clinical sites and all participants provided written informed consent. 
| NGS subpopulation
| Definition of HBV-DR variants
To focus on variants that have been confirmed to be associated with 
| HBV Genotype
| Statistical analyses
Summary statistics were presented for the overall sample.
Demographic, clinical and virological characteristics were described using frequency and percent for categorical variables and median (in- 
| RESULTS
| Characteristics of the study population
As of 5 July 2016, 1993 participants were enrolled into the HBRN Cohort Study. For this analysis, 430 participants were excluded because they were found to be either HBsAg negative at enrolment or belonged to groups that were specifically targeted for enrolment (participants with acute hepatitis B, flares of chronic hepatitis B (CHB), or hepatitis D coinfection; participants who were pregnant, or were potential candidates for HBRN clinical trials or immunology study). In total, 1342 participants were included in the analysis of prevalence of and risk factors associated with HBV-DR variants based on Sanger sequencing. All 1342 participants included were enrolled prior to switching from "consecutive" to "targeted" enrolment, and all samples used in this study were collected between 2011 and 2014.
Median age of the participants studied was 42 years, and 51% were men. A majority of the participants were Asian (75%), born outside the USA or Canada (82%). Approximately one-quarter (26%) were hepatitis B e antigen (HBeAg) positive, median HBV DNA level was 4.0 log 10 IU/mL, and one-third had alanine aminotransferase (ALT) level within normal range (≤30 U/L for men and ≤20 U/L for women). The predominant HBV genotypes were B (39%) and C (33%) followed by A (18%) and D (7%) ( Table 1) .
One hundred and forty-two (10.6%) participants had received
NUCs previously ranging in duration from 0.5 to 144 months (median 19.2). The total duration of NUC treatment was <1 year in 41%, 1-3 years in 36%, and >3 years in 23% of treated participants. All 142 participants treated with NUCs had stopped treatment ≥90 days prior to DR variant testing with the vast majority (91.4%) having stopped NUCs >6 months before testing. The most common prior NUC was lamivudine (n=67), with similar numbers having previously received adefovir (23), entecavir (28), or tenofovir (20) and very few having received telbivudin (Table 2 ).
| Prevalence of primary and secondary HBV-DR variants based on Sanger sequencing
Sixteen ( Among 1993 participants enrolled, 11 were excluded because they were found to be HBsAg negative at enrolment based on testing at the central laboratory and 419 were excluded because they had acute HBV or HDV infection or belong to special groups enrolled after the protocol was switched from "consecutive" to "targeted" enrolment. Of the 1563 potentially eligible participants, 198 were excluded because samples within the first 24 weeks of enrolment were not available or HBV-DR resistance data were not available (mostly due to low viremia precluding sequencing). An additional 23 participants were excluded because research samples were collected after the participants started treatment or within 90 days of stopping treatment or dates of HBV treatment were unknown. Thus, 1342 participants were included in the analysis. Table 2 ).
Drug Resistance Data
In total, 38 (2.8%) participants had either primary or secondary HBV-DR variants detected by Sanger sequencing. The prevalence of T A B L E 1 (Continued) primary and secondary HBV-DR variants detected by Sanger sequencing by prior NUC therapy is shown in Figure 2. 
| Prevalence of primary and secondary HBV-DR variants based on NGS
One hundred and ten participants with >90 days prior NUC exposure and available Sanger sequencing data and 110 participants with no prior NUC exposure matched for HBV genotype and baseline HBV DNA level were selected for NGS. Next generation sequencing data were obtained for 132/220 (60%) participants: 66 with and 66 without prior NUC. Next generation sequencing data were not available for the other 88 participants, 44 in each group, due to insufficient sample or inadequate coverage of the region of interest. There were no differences in demographics, HBV genotype, HBV DNA level, ALT level and interval between stopping NUC and sample collection (in those who had prior NUC therapy) between the 132 participants with and 88 without NGS data (data not shown).
Characteristics of the 66 participants with and 66 participants without prior NUC exposure with NGS data were similar except that the group with prior NUC was more likely to be Asian (P<.01) and to be younger (P<.01) ( Table 3) . Among these 132 participants, NGS detected primary HBV-DR variants in 18 (13.6%) participants: eight (12.1%) with and 10 (15.2%) without prior NUC therapy. In contrast, Sanger sequencing detected primary HBV-DR variants in four (3.0%) participants: one (1.5%) with and three (4.5%) without prior NUC therapy. When detected using both methods, the primary HBV-DR variants detected by Sanger sequencing and NGS were concordant in three and discrepant in one participant (#19) where NGS revealed an A181F variant that has not been confirmed to be associated with resistance to HBV NUC, while Sanger showed an A181V variant ( Table 4) .
Next generation sequencing confirmed the presence of secondary HBV-DR variants detected by Sanger sequencing in three participants and detected secondary HBV-DR variants in seven additional participants, making a total of 10 (7.6%): six (9.1%) with and four (6.1%) without prior NUC therapy (Tables 3 and 4 
Among the primary HBV-DR variants detected by NGS but not by
Sanger sequencing, T184A/S was the most common variant observed, while V173L and L180M were the most common secondary HBV-DR variants detected by NGS but not by Sanger sequencing (Table 4 ).
In total, 28 of 132 (21%) participants had either primary or secondary HBV-DR variants detected by NGS. Of these, eight (#3, 4, 5, 7, 8, 10, 14 and 23) received NUC therapy after sample collection for HBV-DR variant testing. All eight received tenofovir, as monotherapy in six and in combination with emtricitabine in the other two participants. Median HBV DNA at the start of NUC treatment was 5 log 10 IU/mL. HBV DNA decreased to levels below quantification in seven, with no breakthrough throughout the course of treatment (range 6.1-58.6 months); the remaining patient had decrease in HBV DNA from 6.3 to 1.4 log 10 IU/mL after 6 months of treatment and was lost to follow-up.
T A B L E 2 Prevalence of primary and secondary HBV-DR variants based on Sanger sequencing, by Prior nucleos(t)ide analogues (NUC) Treatment (N=1342)
Prior
F I G U R E 2 Prevalence of primary and secondary HBV-DR variants in relation to prior nucleos(t)ide analogues therapy
| DISCUSSION
In this study of 1342 persons with chronic HBV infection living in the US and Canada, who were not receiving HBV NUC therapy >90 days before enrolment in the HBRN Cohort Study, we found a low prevalence of both primary and secondary HBV-DR variants using Sanger sequencing, 1.2% and 1.7%, respectively, and 2.8% overall. Participants with and without a prior history of NUC therapy had similar rates of primary HBV-DR variants, 1.4% vs 1.2%, respectively.
As expected, the more sensitive assay (NGS) detected a higher rate of primary (13.6%) and secondary (7.6%) HBV-DR variants (21% overall), with no difference between participants with and those without prior In our study, 69.3% of the participants were born in Asia and 8.9%
in Africa, and likely acquired HBV infection in their home countries.
Despite this, the prevalence of HBV-DR variants among participants in our study who had not received NUC therapy was substantially lower than that reported in the studies from Asia and Africa. This may be related to the fact that more than half of our participants born outside the US and Canada immigrated more than 10 years prior to enrolment into this study, which was before NUCs were in widespread use in Asia and Africa. Four other US studies that included 713 persons, predominantly Asians who had not received NUC therapy, had a similarly low prevalence of HBV-DR variants with a pooled prevalence of 0.71% (95% CI 0-1.34) based on Sanger sequencing or reverse hybridization. 6, [10] [11] [12] [13] These findings support that HBV-DR variants are rarely found by Sanger sequencing among untreated persons with chronic HBV infection who reside in the US and Canada, and transmission of these variants to HBV-susceptible persons is uncommon. It should be noted that due to a high error rate during replication of HBV DNA, these variants may have emerged spontaneously and may not have been acquired at the time of infection. Although we found a higher prevalence of HBV-DR variants by NGS, the clinical significance of these variants present as a minor species is unclear, and most studies reported no impact of these minor variants on response to NUC therapy. [14] [15] [16] Of the eight participants with DR variants detected by NGS who subsequently started NUC therapy, five had primary DR variants detected by NGS but none by Sanger sequencing. All eight had rapid virologic responses, and none had virologic breakthrough throughout the course of treatment.
HBV-DR variants selected during NUC therapy generally revert back to wild-type sequence after withdrawal of NUC therapy, although these variants may be archived and can be rapidly selected upon reexposure to the same NUC or other NUCs with cross resistance. In our study, we found that the prevalence of HBV-DR variants based on Sanger sequencing as well as NGS among participants with prior NUC was not higher than those without prior NUC, even though some had received NUC for more than 3 years. This may be related to the use of entecavir or tenofovir as first-line therapy in recent years, and the fact that majority of the treated participants had stopped NUC more than 6 months before testing. In addition, while NGS is more sensitive than Sanger in detecting minor variants, HBV-DR variants may represent such a low proportion of the virus pool after withdrawal of NUC that NGS may still fail to identify all cases.
Our study had a few limitations. The study population consisted of persons followed at tertiary care centres and may not be completely reflective of the general population with chronic HBV infection in the USA or Canada. Testing for DR variants with NGS was not possible in 40% of the samples, limiting the robustness of our conclusion on the prevalence of HBV-DR variants when tested by highly sensitive assays. However, the only difference between participants with NGS data and those in whom we had a technical failure with NGS was a shorter duration of prior NUC in those with NGS data, median 18.5 vs 25.1 months. All eight participants with baseline HBV-DR variants who subsequently received NUC therapy had rapid virologic responses with no breakthrough but the number is too small for us to ascertain the impact of these variants on response to NUC therapy. In clinical trials and in clinical practice, baseline testing for HBV-DR variants is not performed prior to initiating NUC therapy, and virological responses to NUC therapy-particularly with the newer NUCs entecavir or tenofovir-are achieved in the vast majority of patients.
In conclusion, our study of more than 1000 persons with chronic HBV infection residing in the US and Canada found a low prevalence of primary and secondary HBV-DR variants regardless of prior NUC therapy, supporting that these variants were either not present or disappear after withdrawal of NUC, and that transmission of these variants from patients receiving NUC to HBV-susceptible persons is probably rare. We confirmed that more sensitive assays such as NGS can detect HBV-DR variants in a higher proportion of persons with chronic HBV infection; however, the clinical significance of these variants present as minor species is uncertain and these variants may have emerged spontaneously. Our results could be related to the al- 
